

Amendments to the Specification:

Please replace paragraph [0049] of the application as published with the following amended paragraph:

[0049] From the known human tshr cDNA information registered in GenBank (<http://www.ncbi.nlm.nih.gov/>) (XM-056624, XM-041159, XM-041157, M73747 and BC009237), cDNA nucleotide sequence was obtained. The full length of human tshr gene was amplified by RT-PCR and cloned into TA vector. The insertion of the human tshr gene was then confirmed by sequencing.

Please replace paragraph [0079] of the application as published with the following amended paragraph:

[0079] Each of coated wells in plate was washed 4-5 times with 200 µl of washing buffer (PBS + 0.2% ~~Tween~~TWEEN20) and then 50 µl of dilution buffer (washing buffer + 5% skim milk) at 4°C was added, followed by incubation in moisture chamber for blocking at 37°C for 1 hr. After blocking, each well was washed with 200 µl of washing buffer 4-5 times. Serum of Grave's disease patient was serially diluted to 1/100, 1/200, 1/400, 1/800, 1/1600, 1/3200, 1/6400 and 1/12800 and 50 µl of the dilute of each concentration was added to from lanes A to H as in FIG. 7 and allowed to stand at 4°C for 2 hrs. As above, each of coated wells in plate was washed with 200 µl of washing buffer and 300 µl of blocking buffer (PBS buffer + 1% BBA, 5% sucrose and 0.05% NaN₃) at 4°C was added, followed by incubated in moisture chamber for blocking at 4°C for 1 hr. After blocking, each well was washed with 200 µl of washing buffer three times. Ten µl of diluted IgG conjugate (peroxidase labeling, 1/1000 dilution) were added and allowed to stand at 4°C for 1 hr.